Masoud Vedadi

University of Toronto
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Human RNA capping is critical for mRNA splicing, protection of RNA from 5′ exonucleases in the cytoplasm, and targeting to the ribosome. Human RNMT, CMTR1, and CMTR2 are RNA methyltransferases involved in the RNA capping process. They play a significant role in the proliferation and differentiation of embryonic stem cells and have been implicated in cancer. Substrate specificities of human RNA capping methyltransferases have been somewhat explored in a few studies. Here, we report on a comprehensive, systematic, and quantitative assessment of their substrate specificities along with SARS‐CoV‐2 counterparts, nsp14 and nsp16. We discovered novel cooperative activities of human enzymes. We designed and synthesized various RNA substrates with defined patterns of methylation to systematically assess the dependency or cooperativity of their activities using radiometric assays followed by mass spectrometry to verify RNA methylation status. We have tested all five enzymes in parallel against these substrates and determined kinetic parameters. Our data not only indicate that the catalytic activities of human RNMT, CMTR1, and CMTR2 are distinct and nonoverlapping, but also provide a novel quantitative assessment of their activities, indicating how and to what extent these proteins affect each other's function. Unlike nsp14 and nsp16, their functions are not necessarily sequential, but show significant cooperativity. Altogether, our data provide a comprehensive understanding of substrate specificities of human RNA capping methyltransferases, enabling the development of potential future anticancer therapeutics and assessment of antiviral therapeutics' selectivity.

Year:

2025

Proteolysis-targeting chimeras (PROTACs) have been explored for the degradation of drug targets, particularly undruggable proteins, for more than two decades. They have been employed by various groups successfully, however only a handful of E3 ligase substrate receptors such as CRBN, VHL, MDM2, and IAP have been efficiently used. Downregulation and mutation of these receptors would reduce the effectiveness of PROTACs, thus necessitating the addition of new substrate receptors and E3 ligases to the repertoire to avoid resistance. We recently developed potent ligands for DCAF1, a substrate receptor of EDVP and CUL4 E3 ligases with diverse substrate specificity. Here, we focused on DCAF1 toward the development of PROTACs for WDR5, a drug target in various cancers. We report three DCAF1-based PROTACs with endogenous and exogenous WDR5 degradation effects and solved the first high-resolution crystal structures of DCAF1-PROTAC-WDR5 ternary complexes. The structures reveal detailed insights into the interaction of DCAF1 with various WDR5-PROTACs, including the finding that PROTACs can compress like a spring to similar effective lengths to keep DCAF1 and WDR5 within interaction distance of each other. Furthermore, specific DCAF1 loops play a significant role in providing surface plasticity needed to interact with different PROTAC-WDR5 complexes, reflecting the mechanism by which DCAF1 functions as a substrate receptor for E3 ligases with diverse sets of substrates.

Year:

2024

Year:

2023

Collaborators (3)

Dalia Barsyte-Lovejoy

University of Toronto

CANADA
View details

Stuart Green

Staff Scientist

University of Toronto

CANADA
View details

Levon Halabelian

Assistant Professor

University of Toronto

CANADA
View details